TABLE 5

Genotypic and phenotypic analysis of GT1b patient viral isolatesa

Dose (mg)GT or patientNadir (h)NS5A RAM(s) at baseline, first 100 aa (%)NS5A RAM(s) at nadir, first 100 aa (%)EDP-239 EC50 (nM)c
BaselineNadirFold change
GT1b (Con1)ReferenceReference0.003
10540472Y93H(4)L28M(32), L31F(22), P58S(46), Y93H(98)0.0020.454272
5409240.0020.0021
305405120.0040.0041
5413b312L31M(34)/V(27), P58S(1), A92K(2), Y93C(6)/H(33)/N(2)0.0030.07125
5414b72Y93H(99)R30Q(7), L31V(7), Y93H(99)1.23.23
100540224R30Q(76)R30Q(17), Q62P(51), Y93C(1)0.0040.0031
5406480.0020.0021
5410120.0020.0021
200540396P58S(99)R30H(53), Y93H(99)0.0021.8809
540824Y93C(8)0.0020.0031
541112R30Q(100), Q62R(100)R30Q(99), Q62R (99)0.0010.0011
  • a aa, amino acids.

  • b The viral RNA levels at nadir viral loads for patients 5413 and 5414 were below 1,000 IU/ml, and the sequence could not be amplified; 72 h was selected for patient 5414 and day 14 for patient 5413.

  • c n = 2 biological replicates.